GI Dynamics Announces New EndoBarrier® Data from Research with GlaxoSmithKline (GSK) Presented during Digestive Disease Week
5/5/2014 7:49:31 AM
GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data from a study with GlaxoSmithKline (NYSE: GSK) on EndoBarrier® and its potential mechanism of action were presented at Digestive Disease Week 2014 (DDW) during an oral presentation titled, “Duodenal-jejunal Bypass Liner Increases Fasting and Postprandial Serum Levels of Bile Acids in Patients with Severe Obesity.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by